en · de · es · fr · pt
melanotan-2-notes.peptides6823.com › Faq › Melanotan-2 Identity And Regulatory Status — 2026 Update

Melanotan-2 Identity And Regulatory Status — 2026 Update

By Editorial Desk · published 2025-09-29 · last reviewed 2025-10-18 · Faq

If you have been reading about Alpha-MSH and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-10-18. Numbers and descriptions here follow the published literature rather than marketing material.

Melanotan-2 Identity And Regulatory Status

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Handling, Storage and Analytical Control

Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.

Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAnalogue of alpha-melanocyte-stimulating hormone
Common synonymsMT-II; melanotan 2No internationally accepted non-proprietary name
Typical presentationLyophilised powder in a sealed vialOften supplied alongside a separate diluent
Regulatory statusUnapproved therapeutic substanceCustoms seizure reported in several jurisdictions
Reported route in useSubcutaneous injectionSelf-administered outside clinical settings

Melanotan-2 Identity and Receptor Pharmacology

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Related pages on this site

Regulatory Status and Literature Discussion

Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.

Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.

Background and Chemical Profile

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Handling, Storage, and Analytical Verification

Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.

Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.

Supporting material

Prigozhin denied the allegations in a Telegram statement on 15 May, while the Kremlin described the report as a hoax. The Ukrainian air force said it destroyed 25 drones and three cruise missiles in another massive overnight attack by Russia. Seven people were killed and another 16 were injured in Russian shelling in Donetsk and Kherson oblasts. Russian-installed officials said mobile internet was temporarily suspended in occupied areas of Luhansk oblast due to increased shelling by Ukrainian troops.

=== FORTUNE, Modern Healthcare and Press Ganey awards === Southern Ohio Medical Center has been recognized as one of FORTUNE Magazine’s Best Places to Work in America for six straight years. In 2013, it came in 29th on the list with FORTUNE noting: “Employees are proud to work for a medical provider that has won numerous awards for patient care, a fact that's reflected in its average tenure. Nearly 20% of the staff has worked there for more than 20 years.” SOMC was recognized on the FORTUNE list again in 2014 (coming in 18th) and 2015 (coming in 44th). In the 2015 survey, 93% of SOMC employees described their workplace as "a great place to work." Modern Healthcare Magazine also recognized SOMC as one of the nation's best healthcare employers in 2010, 2011 and 2012. In 2012, Southern Ohio Medical Center was one of only 13 Press Ganey clients in the nation to be chosen as a Distinctive Workplace Award winner. The award was given to organizations that reached, and sustained, the 95th percentile in employee satisfaction – SOMC was at the 99th percentile.

→ However, IUPAC structure based nomenclature is based on naming of the preferred constitutional repeating unit. IUPAC has also issued guidelines for abbreviating new polymer names. 138 common polymer abbreviations are also standardized in the standard ISO 1043–1.

Sources: en.wikipedia.org

Notes from published material

== G == Gabriel ethylenimine method Gabriel synthesis Gabriel–Colman rearrangement, Gabriel isoquinoline synthesis Gallagher–Hollander degradation Gassman indole synthesis Gastaldi synthesis Gattermann aldehyde synthesis Gattermann Koch reaction Gattermann reaction Geminal halide hydrolysis Gewald reaction Gibbs phthalic anhydride process Gilman reagent Glaser coupling Glycol cleavage Goldberg reaction Gomberg–Bachmann reaction Gomberg–Bachmann–Hey reaction Gomberg radical reaction Gould–Jacobs reaction Graebe–Ullmann synthesis Grignard degradation Griesbaum coozonolysis Grignard reaction Grob fragmentation Grubbs' catalyst in Olefin metathesis Grundmann aldehyde synthesis Gryszkiewicz–Trochimowski and McCombie method Guareschi–Thorpe condensation Guerbet reaction Gutknecht pyrazine synthesis

== Adverse effects == Adverse effects include drowsiness, dizziness, weakness, fatigue, headache, trouble sleeping, nausea and vomiting, poor concentration and recall (resembling dementia), urinary retention, or constipation.

The architecture of Brazil is influenced by Europe, especially Portugal. It has a history that goes back 500 years to the time, when Pedro Álvares Cabral landed in Brazil in 1500. Portuguese colonial architecture was the first wave of architecture to go to Brazil. It is the basis for all Brazilian architecture of later centuries. In the 19th century, during the time of the Empire of Brazil, the country followed European trends and adopted Neoclassical and Gothic Revival architecture. Then, in the 20th century, especially in Brasília, Brazil experimented with modernist architecture. The colonial architecture of Brazil dates to the early 16th century, when Brazil was first explored, conquered and settled by the Portuguese. The Portuguese built architecture familiar to them in Europe in their aim to colonize Brazil. They built Portuguese colonial architecture, which included churches and civic architecture, including houses and forts, in Brazilian cities and the countryside. During the 19th century, Brazilian architecture saw the introduction of more European styles to Brazil, such as Neoclassical and Gothic Revival architecture. This was usually mixed with Brazilian influences from their own heritage. In the 1950s modernist architecture was introduced when Brasília was built as a new federal capital in the interior of Brazil to help develop the interior. The architect Oscar Niemeyer idealized and built government buildings, churches and civic buildings in the modernist style.

Sources: en.wikipedia.org

Background from the literature

The historian Sergio Luzzatto recounted that in 1919, Maria De Vito (the cousin of the local pharmacist Valentini Vista at Foggia) testified that the young Pio bought carbolic acid and the great quantity of four grams of veratrine "without presenting any medical prescription whatsoever". Pio maintained that the carbolic acid was used to sterilize syringes used for medical treatments and that after being subjected to a practical joke where veratrine was mixed with snuff tobacco, causing uncontrollable sneezing after ingestion, he decided to acquire his own quantity of the substance in order to play the same joke on his confreres. Amico Bignami in a report wrote that the wounds were caused by "neurotic necrosis". He suggested they had been inflicted unconsciously by suggestion and artificially maintained by iodine that Pio had used as a disinfectant. In 1922, physician Agostino Gemelli went to visit Padre Pio where he observed and interviewed him, but Gemelli was denied the right to physically examine the stigmata without an authorization from the Holy Office. Gemelli, irritated and offended for not being allowed to directly examine the stigmata, wrote while reviewing the previous reports, that Pio was a hysteric and his stigmata were self-induced, not of supernatural origin. Gemelli also speculated that his wounds were kept open with carbolic acid. Giorgio Festa, who examined the stigmata of the friar on October 28, 1919, wrote in his report that they "are not the product of a trauma of external origin, nor are they due to the application of potently irritating chemicals".

{\displaystyle {\begin{aligned}{\frac {N}{N_{0}}}&=4/14\approx 0.286,\\\tau &={\frac {T_{1/2}}{\ln 2}}\approx 8267{\text{ years}},\\t&=-\tau \,\ln {\frac {N}{N_{0}}}\approx 10356{\text{ years}}.\end{aligned}}}

The pore sizes of technical membranes are specified differently depending on the manufacturer. One common distinction is by nominal pore size. It describes the maximum pore size distribution and gives only vague information about the retention capacity of a membrane. The exclusion limit or "cut-off" of the membrane is usually specified in the form of NMWC (nominal molecular weight cut-off, or MWCO, molecular weight cut off, with units in Dalton). It is defined as the minimum molecular weight of a globular molecule that is retained to 90% by the membrane. The cut-off, depending on the method, can by converted to so-called D90, which is then expressed in a metric unit. In practice the MWCO of the membrane should be at least 20% lower than the molecular weight of the molecule that is to be separated. Using track etched mica membranes Beck and Schultz demonstrated that hindered diffusion of molecules in pores can be described by the Rankin equation. Filter membranes are divided into four classes according to pore size:

1949), right wing conservative cultural critic; contributing editor to City Journal, published by Manhattan Institute, where he is the Dietrich Weismann Fellow; his work has appeared in The British Medical Journal, The Times, New Statesman, The Observer, The Daily Telegraph, The Spectator, The Salisbury Review, National Review, New English Review, The Wall Street Journal and Axess magasin; author of Life at the Bottom: The Worldview That Makes the Underclass, Our Culture, What's Left of It and Spoilt Rotten: The Toxic Cult of Sentimentality; his writing argues that leftist views prevalent within Western intellectual circles minimise responsibility of individuals for their own actions and undermine traditional mores, contributing to the formation within prosperous countries of an underclass afflicted by endemic violence, criminality, sexually transmitted diseases, welfare dependency, and drug abuse. Dalrymple was awarded Prize for Liberty by the Flemish classical-liberal think-tank Libera!. John Diamond, journalist Alf Dubs, Baron Dubs (b.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II approved for medical use?

No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.

Where did melanotan II originate?

It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.

Why is purity a concern for unapproved peptides?

Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.

How is peptide purity usually reported?

Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.

Network